WISER and Optomed established a Joint Venture to Transform Eye-Screening and Primary Healthcare Services in China

HELSINKI & GUANGZHOU-Aug 11, 2025, Optomed Plc (HEL: OPTOMED), a publicly listed company in Finland, specializing in AI fundus cameras and eye screening solution, and WISER Group, a China-based investment and venture development partner, today announced the establishment of a joint venture (JV) to scale AI eye-screening services across China.

This collaboration combines Optomed’s cutting-edge eye-screening solutions with WISER’s deep market expertise, to address China’s growing demand for preventative eye-screening services. The newly formed JV is set to establish a nationwide eye screening network in China, via Optomed’s world first FDA-certified AI fundus camera Aurora and eye-screening solution, to address the growing demand for accessible and affordable eye-screening services of diabetes and other chronic diseases across China. 

With over 600 million people in China suffering from eye problems and 140 million living with diabetes, National Health Commission of China (NHC) announced an action-plan in 2021 to promote nation-wide eye screening and chronic disease prevention in the coming years. AI eye-screening for diabetes and other diseases has been well adopted by leading eye hospitals, and the deployment of eye-screening services in primary healthcare, e.g residential communities hospitals, has been driven by top eye-doctors and China government since 2025. Optomed’s AI eye-screening solution perfectly addressed this growing demand in China. 

"We are glad to establish the JV with WISER to scale up our eye-screening solution in China," said Petri Salonen, Chairman of Optomed. "Our AI fundus camera disrupts the diabetes screening and other eye diseases, now we’re ready to bring this proven solution to the massive China market with WISER."

"Optomed’s disruptive AI eye-screening solution aligns perfectly with China’s healthcare priorities," added Kevin Chen, CEO of WISER. "This JV creates a scalable platform to improve diabetes screening and eye-care services nationwide, and bridges the gap between the fast-growing patients and shortage of eye-doctors, meanwhile to enable China government & hospitals establish a comprehensive health database, preventing diabetes and a number of other diseases, saving lives and healthcare spending for China."

About Optomed 

Optomed was founded in Finland in 2004, with the vision to design a cost-effective handheld fundus camera to improve the efficiency of eye screenings and to enable screening for all. Our AI-powered screening solutions are designed to transform diagnostic processes and enable early detection of diabetes and a number of other diseases. Optomed has developed a strong international patent portfolio comprising 52 international patents and 5 pending patents. Optomed has offices in Finland, US and China and the company’s products are sold in over 60 countries globally.

For more info, please check: www.optomed.com